A Phase II Study of Lenalidomide Intensification in Patients with Asymptomatic Multiple Myeloma that Has Progressed with Lenalidomide Maintenance Therapy after Autologous Stem Cell Transplantation

Full Title
A Phase II Clinical Trial of Lenalidomide Intensification in Patients with Serologic/Asymptomatic Progression of Multiple Myeloma While on Lenalidomide Maintenance
Disease Status
Newly Diagnosed

Low-dose “maintenance” lenalidomide is the usual treatment for patients with multiple myeloma after autologous stem cell transplantation. However, the disease typically returns. In this study, researchers are determining if giving higher doses of lenalidomide to patients with multiple myeloma that has progressed on maintenance lenalidomide but has not yet caused any organ damage is safe and effective for controlling the disease.


To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have evidence of a return of multiple myeloma after autologous stem cell transplantation and receipt of lenalidomide maintenance therapy.
  • Patients may not yet have symptoms of multiple myeloma or organ damage.
  • Patients must be age 18 or older.

For more information about this study and to inquire about eligibility, please contact Dr. Hani Hassoun at 212-639-3228.

Hematology: Multiple Myeloma
Related Diseases